gefitinib has been researched along with Cancer of Prostate in 77 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 55 (71.43) | 29.6817 |
| 2010's | 19 (24.68) | 24.3611 |
| 2020's | 3 (3.90) | 2.80 |
| Authors | Studies |
|---|---|
| Arlot, Y; Depreux, P; Farce, A; Garofalo, A; Goossens, L; Lemoine, A | 1 |
| Goodfellow, E; Huang, S; Jean-Claude, BJ; Schmitt, J; Williams, C | 1 |
| Freeman, MR; Hemler, ME; Sharma, C; Steen, H; Yang, W | 1 |
| Aberlenc, A; Bawa, O; Chauchereau, A; Farace, F; Faugeroux, V; Honore, A; Lacroix, L; Laplace-Builhe, C; Marty, V; Oulhen, M; Pawlikowska, P; Pommier, AL; Rouffiac, V; Scoazec, JY; Tayoun, T | 1 |
| Hameed, I; Lin, JZ; Ren, ZY; Xu, Z; Yu, Y; Zhu, JG | 1 |
| Chen, FH; Chiang, CS; Fu, SY; Hong, JH; Wang, CC; Yang, YC | 1 |
| Bollu, LR; Gao, G; Huang, WC; Hung, MC; Ren, J; Su, F; Weihua, Z; Xu, L | 1 |
| Lin, J; Pan, W; Shi, H; Wu, H; Yu, H; Zhu, J | 1 |
| Brame, LS; Cao, A; Fang, YT; Fung, KM; Humphreys, MR; Kropp, BP; Lin, HK; Shih, PT; Wu, W; Yang, Q | 1 |
| Saya, H; Yoshida, GJ | 1 |
| Hagiyama, M; Inoue, T; Ito, A; Naito, Y; Nojima, H; Okamoto, A; Okuzaki, D; Ozaki, Y; Sakurai, MA; Sasakura, T; Tabara, H; Yabuta, N | 1 |
| Bubendorf, L; Erne, P; Frachet, A; Frismantiene, A; Kyriakakis, E; Maslova, K; Pfaff, D; Philippova, M; Resink, TJ; Ruiz, C; Vlajnic, T | 1 |
| Battaglia, M; Boccardo, F; Conti, G; Cruciani, G; Lapini, A; Manganelli, A; Ricci, S; Rubagotti, A | 1 |
| Corman, J; Isacson, C; Kozlowski, P; Picozzi, V; Porter, C; Vaughan, M; Vuky, J | 1 |
| Curigliano, G; de Braud, F; De Cobelli, O; Sbanotto, A; Scardino, E; Spitaleri, G | 1 |
| Boyer, MJ; Davis, ID; Gurney, H; Kotasek, D; Pezaro, C; Rosenthal, MA; Solomon, B; Toner, GC; Underhill, C | 1 |
| Collan, J; Hemminki, A; Isola, J; Joensuu, G; Joensuu, T; Kouri, M; Kupelian, PA; Nokisalmi, P; Pesonen, S; Reddy, C; Ruutu, M | 1 |
| Baldi, E; Forti, G; Gelmini, S; Maggi, M; Marchiani, S; Nesi, G; Orlando, C; Paglierani, M; Tamburrino, L | 1 |
| Agus, DB; Favero, K; Hodge, A; Jain, A; Mink, S; Penuel, E; Schmidt, J; Tindell, C | 1 |
| Batra, SK; Depreux, P; Henichart, JP; Johansson, SL; Mimeault, M | 1 |
| Markaverich, BM; Rodriguez, M; Shoulars, K; Vijjeswarapu, M | 1 |
| Dondi, D; Festuccia, C; Gravina, GL; Locatelli, A; Motta, M; Piccolella, M; Tombolini, V | 1 |
| Collan, J; Hemminki, A; Joensuu, G; Joensuu, T; Nupponen, N; Pesonen, S; Ruutu, M | 1 |
| Jongstra, J; Siu, A; Virtanen, C | 1 |
| Carrión-Salip, D; De Llorens, R; Massaguer, A; Menendez, JA; Oliveras, G; Pandiella, A; Panosa, C; Puig, T | 1 |
| Aldinucci, D; Borghese, C; Cattaruzza, L; Celegato, M; Colombatti, A; De Luca, A; Mazzucato, M; Normanno, N; Pivetta, E | 1 |
| Ranson, M | 1 |
| Albanell, J; Averbuch, SD; Baselga, J; Bjork, T; Calvert, H; Feyereislova, A; Gianni, L; Harris, A; Kaye, SB; Kieback, DG; Ranson, M; Raymond, E; Rischin, D; Rojo, F; Swaisland, H | 1 |
| Chen, J; Lee, F; Scher, HI; She, Y; Sirotnak, FM | 1 |
| Lorusso, PM | 1 |
| Schiller, JH | 1 |
| Angelucci, A; Bologna, M; Festuccia, C; Gravina, GL; Marronaro, A; Vicentini, C | 1 |
| Blackledge, G | 1 |
| Kawashima, H; Kurisu, T; Nakatani, T; Sugimura, K; Sugita, S; Tanaka, T | 1 |
| Baldi, E; Bonaccorsi, L; Forti, G; Marchiani, S; Muratori, M | 1 |
| Agrawal, S; Bianco, AR; Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; Ficorella, C; Tortora, G | 1 |
| Ardito, R; Bianchino, G; Boninsegna, A; Camerini, A; Cittadini, A; Faraglia, B; Sgambato, A; Spada, D; Valentini, V | 1 |
| Armstrong, EA; Benavente, S; Chinnaiyan, P; Harari, PM; Huang, S | 1 |
| Depreux, P; Hénichart, JP; Jouy, N; Mimeault, M | 1 |
| Von Pawel, J | 1 |
| Baldi, E; Bonaccorsi, L; Carloni, V; Forti, G; Marchiani, S; Muratori, M | 1 |
| Hansen, FD; Nexø, E; Sørensen, BS; Tørring, N; Ørntoft, TF | 1 |
| Baetz, T; Berry, S; Brundage, M; Canil, CM; Chi, KN; Douglas, L; Ernst, DS; Fisher, B; McKenna, A; Moore, MJ; Pollak, M; Seymour, L; Winquist, E | 1 |
| Vanchieri, C | 1 |
| Angelucci, A; Bologna, M; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Vicentini, C | 1 |
| Earp, HS; Gregory, CW; Liu, Y; Majumder, S; McCall, W; Mohler, JL; Sartor, CI; Whang, YE | 1 |
| Angelucci, A; Biordi, L; Bologna, M; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Vicentini, C | 1 |
| Etienne-Grimaldi, MC; Fischel, JL; Formento, P; Gérard, F; Gugenheim, J; Hannoun-Levi, JM; Mazeau, C; Milano, G | 1 |
| Afar, DE; Agus, DB; Aronson, N; Curran, J; Galkin, A; Hunter, JB; Jain, A; Laux, I; Natale, RB; Shak, S; Tindell, CA | 1 |
| Batra, SK; Depreux, P; Hénichart, JP; Lin, MF; Mimeault, M; Moniaux, N; Moore, E | 1 |
| Angelucci, A; Biordi, L; Bologna, M; Dolo, V; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Speca, S; Vicentini, C | 1 |
| Bianco, AR; Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; Melisi, D; Tortora, G; Veneziani, BM | 1 |
| Guan, JY; Hour, TC; Hsieh, MW; Huang, CY; Lin, CC; Lin, SR; Liu, GY; Pu, YS; Wang, CW | 1 |
| Bellezza, I; Bracarda, S; Caserta, C; Minelli, A | 1 |
| Das-Gupta, A; Small, E; Soulie, P; Trump, D; Wilding, G | 1 |
| Gullick, WJ; Normanno, N | 1 |
| Angelucci, A; Bologna, M; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Rucci, N; Teti, A; Vicentini, C | 1 |
| Hirata, H; Iizuka, N; Inoue, R; Matsumoto, H; Matsuyama, H; Miura, K; Naito, K; Ohmi, C; Shirai, M; Yano, S | 1 |
| Hoshinaga, K; Kuwahara, Y; Maruyama, T; Sakurai, T; Shiroki, R | 1 |
| Nakayama, M; Nishimura, K; Nonomura, N; Okuyama, A; Takayama, H | 1 |
| Batra, SK; Depreux, P; Henichart, JP; Johansson, SL; Lin, MF; Mimeault, M; Moore, E; Venkatraman, G | 1 |
| Briand, O; Depreux, P; Desroses, M; Farce, A; Hénichart, JP; Laconde, G; Lemoine, A; Pommery, N; Telliez, A | 1 |
| Curigliano, G; de Braud, F; De Cobelli, O; De Pas, T; Manzotti, M; Pelosi, G; Renne, G; Spitaleri, G | 1 |
| Batra, SK; Depreux, P; Henichart, JP; Johansson, SL; Lin, MF; Mimeault, M; Moore, E; Vankatraman, G | 1 |
| Borner, M; Knuth, A; Morant, R; Pedrazzini, A; Rochlitz, C; Roggero, E; Salzberg, M; Schönenberger, A; Thalmann, G | 1 |
| Bologna, M; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Ricevuto, E; Speca, S; Vicentini, C | 1 |
| Curigliano, G; De Braud, F; De Cobelli, O; De Pas, T; Matei, V; Noberasco, C; Nolè, F; Renne, G; Rocco, B; Scardino, E; Spitaleri, G; Teresa Sandri, M; Verweij, F; Zorzino, L | 1 |
| DiPaola, RS; Fontana, J; Iacona, RB; Kabbinavar, FF; Rubin, M; Small, EJ; Tannir, N; Wilding, G | 1 |
| Almaraz-Pro, C; Colás, B; Colomer, R; Cortés, MA; López-Ruiz, P; Martín-Orozco, RM; Rodríguez-Ubreva, FJ; Ropero, S | 1 |
| Barrow, D; Gee, JM; Hutcheson, IR; Jones, HE; Knowlden, JM; Nicholson, RI | 1 |
| Biordi, L; Bologna, M; Festuccia, C; Gravina, GL; Martella, O; Muzi, P; Ronchi, P; Vicentini, C | 1 |
| Blume, JE; Miller, CC | 1 |
| Batra, SK; Depreux, P; Hauke, R; Henichart, JP; Lin, MF; Mehta, PP; Mimeault, M | 1 |
| Conaway, M; Gioeli, D; Theodorescu, D; Weber, MJ; Wu, Z | 1 |
| Kris, MG; Miller, VA; Scher, HI; Sirotnak, FM; Zakowski, MF | 1 |
| Barton, J; Blackledge, G; Wakeling, A | 1 |
7 review(s) available for gefitinib and Cancer of Prostate
| Article | Year |
|---|---|
ZD1839 (Iressa): for more than just non-small cell lung cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Combined Modality Therapy; Controlled Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Treatment Outcome | 2002 |
Phase I studies of ZD1839 in patients with common solid tumors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Morpholines; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
New directions for ZD1839 in the treatment of solid tumors.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Growth factor receptor tyrosine kinase inhibitors; clinical development and potential for prostate cancer therapy.
Topics: Epidermal Growth Factor; Gefitinib; Humans; Male; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptors, Growth Factor | 2003 |
Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Quinazolines | 2004 |
Targeting of EGFR tyrosine kinase by ZD1839 ("Iressa") in androgen-responsive prostate cancer in vitro.
Topics: Androgens; ErbB Receptors; Gefitinib; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2006 |
Growth factors and their receptors: new targets for prostate cancer therapy.
Topics: Antibodies, Bispecific; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; ErbB Receptors; Gefitinib; Humans; Male; Neoplasms, Hormone-Dependent; Oligonucleotides, Antisense; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Trastuzumab | 2001 |
13 trial(s) available for gefitinib and Cancer of Prostate
| Article | Year |
|---|---|
Prednisone plus gefitinib versus prednisone plus placebo in the treatment of hormone-refractory prostate cancer: a randomized phase II trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Double-Blind Method; Gefitinib; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Hormone-Dependent; Placebos; Prednisone; Prognosis; Prostatic Neoplasms; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Follow-Up Studies; Gefitinib; Humans; Immunoenzyme Techniques; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prostatectomy; Prostatic Neoplasms; Quinazolines; Risk Factors; Taxoids; Treatment Outcome | 2009 |
Health-related quality of life in patients with hormone refractory prostate cancer receiving gefitinib.
Topics: Activities of Daily Living; Adenocarcinoma; Administration, Oral; Aged; Analgesics; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Pain; Pain Measurement; Prostatic Neoplasms; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Time Factors; Treatment Failure | 2009 |
An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Orchiectomy; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Risk Assessment; Single-Blind Method; Survival Analysis; Testosterone; Treatment Outcome | 2009 |
A phase I/II trial of gefitinib given concurrently with radiotherapy in patients with nonmetastatic prostate cancer.
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Gefitinib; Humans; Interleukin-1alpha; Interleukin-6; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Radiotherapy Dosage; Tumor Necrosis Factor-alpha | 2010 |
A phase II trial of gefitinib in patients with rising PSA following radical prostatectomy or radiotherapy.
Topics: Antineoplastic Agents; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Gefitinib; Humans; Male; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Quinazolines; Treatment Outcome | 2012 |
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Prostatic Neoplasms; Quinazolines; Skin; Treatment Outcome | 2002 |
Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatigue; Gefitinib; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines | 2005 |
Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Docetaxel; Estramustine; Gefitinib; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Taxoids | 2006 |
Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib.
Topics: Adenocarcinoma; Adolescent; Adult; Antineoplastic Agents; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Humans; Male; Mutation; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines | 2007 |
An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Gefitinib; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Disease Progression; Drug Resistance, Neoplasm; Endpoint Determination; Gefitinib; Genes, erbB-1; Genes, erbB-2; Humans; Immunohistochemistry; Male; Middle Aged; Pain Measurement; Prostatic Neoplasms; Quality of Life; Quinazolines; Surveys and Questionnaires | 2007 |
A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Gefitinib; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Treatment Outcome | 2007 |
57 other study(ies) available for gefitinib and Cancer of Prostate
| Article | Year |
|---|---|
Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer.
Topics: Amides; Antineoplastic Agents; Carbamates; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Urea; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Design and Synthesis of a Trifunctional Molecular System "Programmed" to Block Epidermal Growth Factor Receptor Tyrosine Kinase, Induce High Levels of DNA Damage, and Inhibit the DNA Repair Enzyme (Poly(ADP-ribose) Polymerase) in Prostate Cancer Cells.
Topics: Cell Line, Tumor; DNA Damage; Down-Regulation; Drug Design; ErbB Receptors; Humans; Male; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Signal Transduction | 2020 |
Antioxidant functions of DHHC3 suppress anti-cancer drug activities.
Topics: Acyltransferases; Antineoplastic Agents; Antioxidants; Apoptosis; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Female; Gefitinib; Humans; Lapatinib; Male; Prostatic Neoplasms; RNA Interference | 2021 |
Exploitation of the chick embryo chorioallantoic membrane (CAM) as a platform for anti-metastatic drug testing.
Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Chick Embryo; Chorioallantoic Membrane; Cisplatin; Crizotinib; Docetaxel; Drug Screening Assays, Antitumor; Gefitinib; Male; Neoplasm Metastasis; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms | 2020 |
Efficacy of gefitinib‑celecoxib combination therapy in docetaxel‑resistant prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Celecoxib; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Docetaxel; Drug Resistance, Neoplasm; Gefitinib; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Prostatic Neoplasms; Quinazolines; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Combination of vessel-targeting agents and fractionated radiation therapy: the role of the SDF-1/CXCR4 pathway.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzimidazoles; Benzylamines; Bone Marrow Cells; Chemokine CXCL12; Combined Modality Therapy; Cyclams; Dose Fractionation, Radiation; ErbB Receptors; Gefitinib; Green Fluorescent Proteins; Heterocyclic Compounds; Luminescent Agents; Male; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pericytes; Prostatic Neoplasms; Quinazolines; Receptors, CXCR4; Tumor Microenvironment | 2013 |
EGFR-SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors.
Topics: Cell Line, Tumor; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Male; Phosphorylation; Prostate; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Purines; Quinazolines; Sodium-Glucose Transporter 1 | 2013 |
Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 leads to greater anti-tumor activity of docetaxel in advanced prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Proliferation; Cyclooxygenase 2; Docetaxel; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; NF-kappa B; Nitrobenzenes; Prostatic Neoplasms; Quinazolines; Sulfonamides; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2013 |
Linking γ-aminobutyric acid A receptor to epidermal growth factor receptor pathways activation in human prostate cancer.
Topics: Autocrine Communication; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; GABA Agonists; GABA Antagonists; gamma-Aminobutyric Acid; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Isonicotinic Acids; Male; Paracrine Communication; Phosphorylation; Picrotoxin; Prostate; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptors, GABA-A; Signal Transduction; src-Family Kinases | 2014 |
EpCAM expression in the prostate cancer makes the difference in the response to growth factors.
Topics: AMP-Activated Protein Kinases; Antigens, Neoplasm; Biomarkers, Tumor; Cell Adhesion Molecules; Cell Line, Tumor; Epidermal Growth Factor; Epithelial Cell Adhesion Molecule; ErbB Receptors; Gefitinib; Humans; Large Neutral Amino Acid-Transporter 1; Male; Neoplastic Stem Cells; Prostatic Neoplasms; Quinazolines; Signal Transduction; Tumor Microenvironment | 2014 |
Gefitinib and luteolin cause growth arrest of human prostate cancer PC-3 cells via inhibition of cyclin G-associated kinase and induction of miR-630.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; ErbB Receptors; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Luteolin; Male; MicroRNAs; Models, Biological; Neoplasm Grading; Phosphorylation; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Quinazolines; Signal Transduction | 2014 |
EGFR and IGF-1R in regulation of prostate cancer cell phenotype and polarity: opposing functions and modulation by T-cadherin.
Topics: Cadherins; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Survival; Collagen; Drug Combinations; ErbB Receptors; Gefitinib; Gene Silencing; Golgi Apparatus; Humans; Laminin; Male; Neoplasm Invasiveness; Phenotype; Phosphorylation; Prostate; Prostatic Neoplasms; Proteoglycans; Pyrimidines; Pyrroles; Quinazolines; Receptor, IGF Type 1 | 2015 |
Androgen-responsive and -unresponsive prostate cancer cell lines respond differently to stimuli inducing neuroendocrine differentiation.
Topics: Androgens; Cell Differentiation; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Male; Neuroendocrine Cells; Phosphopyruvate Hydratase; Prostatic Neoplasms; Quinazolines; Receptors, Androgen | 2010 |
HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation.
Topics: Animals; Cell Growth Processes; Cell Line, Tumor; Dimerization; Down-Regulation; ErbB Receptors; Female; Gefitinib; Humans; Male; Mice; Phosphorylation; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Signal Transduction; Up-Regulation | 2010 |
Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells.
Topics: Adenocarcinoma; Apoptosis; Cell Fractionation; Cell Line, Tumor; Cell Proliferation; Cytotoxins; Docetaxel; Drug Evaluation, Preclinical; ErbB Receptors; Gefitinib; Humans; Male; Neoplasm Invasiveness; Phosphorylation; Prostate; Prostatic Neoplasms; Quinazolines; Taxoids; Transcription Factors; Veratrum Alkaloids; Zinc Finger Protein GLI1 | 2010 |
Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Luteolin; Male; Prostatic Neoplasms; Quinazolines; Signal Transduction | 2010 |
Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle; Cell Division; Drug Synergism; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gonadotropin-Releasing Hormone; Humans; Male; p38 Mitogen-Activated Protein Kinases; Prostatic Neoplasms; Quinazolines; Tumor Cells, Cultured | 2010 |
PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Male; MAP Kinase Signaling System; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-pim-1; Pyridazines; Quinazolines; RNA Interference; RNA, Small Interfering; Tumor Suppressor Proteins | 2011 |
Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
Topics: Androgens; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Betacellulin; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Intercellular Signaling Peptides and Proteins; Male; Neuregulin-1; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; RNA, Messenger | 2012 |
Gefitinib inhibits the cross-talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity.
Topics: Cell Communication; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Chemokine CCL5; Chemotaxis; Culture Media, Conditioned; Docetaxel; ErbB Receptors; Gefitinib; Humans; Male; Mesenchymal Stem Cells; Osteoblasts; Osteoclasts; Osteogenesis; Phosphorylation; Prostatic Neoplasms; Quinazolines; Subcellular Fractions; Taxoids | 2013 |
Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer.
Topics: Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carboplatin; Disease Models, Animal; ErbB Receptors; Female; Gefitinib; Humans; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Nitriles; Paclitaxel; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptors, Androgen; Testosterone; Tosyl Compounds; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Division; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; In Vitro Techniques; Male; Phosphorylation; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Tumor Cells, Cultured; Tyrosine | 2003 |
Effect of type I growth factor receptor tyrosine kinase inhibitors on phosphorylation and transactivation activity of the androgen receptor in prostate cancer cells: Ligand-independent activation of the N-terminal domain of the androgen receptor.
Topics: Androgens; Enzyme Inhibitors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Ligands; Luciferases; Male; Mitogen-Activated Protein Kinases; Phosphorylation; Promoter Regions, Genetic; Prostatic Neoplasms; Protein Structure, Tertiary; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Trans-Activators; Transcriptional Activation; Transfection; Tumor Cells, Cultured | 2004 |
Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation.
Topics: Antineoplastic Agents; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Immunoprecipitation; In Situ Nick-End Labeling; Male; Phosphatidylinositol 3-Kinases; Phosphorylation; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2004 |
Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Fibroblast Growth Factor 2; Gefitinib; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Nuclear Proteins; Oligonucleotides, Antisense; Phosphorylation; Prostatic Neoplasms; Protein Biosynthesis; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-mdm2; Quinazolines; Time Factors; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2004 |
Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells.
Topics: Androgen Antagonists; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Drug Synergism; ErbB Receptors; Flutamide; Gefitinib; Humans; Male; Prostatic Neoplasms; Quinazolines; Tumor Suppressor Proteins | 2004 |
Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cetuximab; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mitogen-Activated Protein Kinases; Phosphorylation; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
Synergistic antiproliferative and apoptotic effects induced by mixed epidermal growth factor receptor inhibitor ZD1839 and nitric oxide donor in human prostatic cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Caspases; Cell Division; Cell Line, Tumor; Ceramides; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Male; Mitochondria; Nitric Oxide Donors; Nitroprusside; Prostatic Neoplasms; Quinazolines; Reactive Oxygen Species | 2005 |
Signaling mechanisms that mediate invasion in prostate cancer cells.
Topics: Androgens; Cell Line, Tumor; Cell Proliferation; Collagen; Drug Combinations; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunoprecipitation; Laminin; Male; Neoplasm Invasiveness; Phenotype; Phosphatidylinositol 3-Kinases; Phosphorylation; Prostatic Neoplasms; Proteoglycans; Quinazolines; Receptors, Androgen; Signal Transduction; Transfection; Tyrosine | 2004 |
Increase in amphiregulin and epiregulin in prostate cancer xenograft after androgen deprivation-impact of specific HER1 inhibition.
Topics: Amphiregulin; Androgens; Animals; EGF Family of Proteins; Epidermal Growth Factor; Epiregulin; ErbB Receptors; Gefitinib; Gene Expression; Glycoproteins; Intercellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; Orchiectomy; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Xenograft Model Antitumor Assays | 2005 |
Scientists hopeful as they uncover molecular clues to prostate cancer.
Topics: Androgen Receptor Antagonists; Androgens; Antineoplastic Agents; Biomarkers, Tumor; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Male; Phosphoric Monoester Hydrolases; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; PTEN Phosphohydrolase; Quinazolines; Receptors, Androgen; Sirolimus; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins; Up-Regulation | 2005 |
Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Cell Division; Cell Line, Tumor; Dihydrotestosterone; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Male; Nitriles; Prostatic Neoplasms; Quinazolines; Tosyl Compounds; Transplantation, Heterologous | 2005 |
Top 10 health stories of 2004.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antidepressive Agents; Antineoplastic Agents; Biomedical Research; Cholesterol, LDL; Cloning, Organism; Coronary Disease; Delivery of Health Care; Dementia; Gefitinib; Humans; Influenza Vaccines; Insurance, Health; Lactones; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Registries; Sulfones; Walking | 2004 |
Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.
Topics: Acetylation; Androgen Receptor Antagonists; Androgens; Cell Line, Tumor; Chromatin; Chromatin Immunoprecipitation; Dihydrotestosterone; ErbB Receptors; Gefitinib; Histones; Humans; Immunoglobulin Fragments; Lapatinib; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Response Elements; Transcription, Genetic | 2005 |
Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
Topics: Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Chemotaxis; Collagen; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Laminin; Male; MAP Kinase Signaling System; Microscopy, Fluorescence; Neoplasm Invasiveness; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Phosphatidylinositol Diacylglycerol-Lyase; Phosphoinositide Phospholipase C; Phosphoric Monoester Hydrolases; Phosphorylation; Prostatic Neoplasms; Proteoglycans; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Proteins; Urokinase-Type Plasminogen Activator | 2005 |
Gefitinib-trastuzumab combination on hormone-refractory prostate cancer xenograft.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Humans; Male; Mice; Mice, Nude; Prostatic Neoplasms; Quinazolines; Trastuzumab; Xenograft Model Antitumor Assays | 2005 |
Epithelial membrane protein-1 is a biomarker of gefitinib resistance.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Models, Animal; Mutation; Neoplasm Proteins; Prostatic Neoplasms; Quinazolines; Receptors, Cell Surface; Xenograft Model Antitumor Assays | 2005 |
Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Proliferation; DNA Damage; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Hedgehog Proteins; Humans; Male; Prostatic Neoplasms; Quinazolines; Signal Transduction; Trans-Activators; Tumor Cells, Cultured; Veratrum Alkaloids | 2006 |
Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Resistance, Neoplasm; ErbB Receptors; G1 Phase; Gefitinib; Humans; Male; Mitogen-Activated Protein Kinase Kinases; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines | 2005 |
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Diphosphonates; Female; Gefitinib; Humans; Imidazoles; Male; Mice; Mice, Nude; Prostatic Neoplasms; Proteins; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays; Zoledronic Acid | 2005 |
Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells.
Topics: Adenocarcinoma; Androgens; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Combinations; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Male; Paclitaxel; Prostatic Neoplasms; Quinazolines | 2006 |
Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application?
Topics: Antineoplastic Agents; Bone Neoplasms; ErbB Receptors; Gefitinib; Humans; Male; Prostatic Neoplasms; Quinazolines; Signal Transduction | 2006 |
Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Culture Media, Conditioned; ErbB Receptors; Gefitinib; Humans; Immunoprecipitation; Incidence; Male; Matrix Metalloproteinase 9; Mice; Mice, Nude; Prostatic Neoplasms; Quinazolines; Signal Transduction; Stromal Cells; Xenograft Model Antitumor Assays | 2006 |
Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer.
Topics: Androgens; Antineoplastic Agents; Cell Growth Processes; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Gene Expression; Humans; Male; Neoplasms, Hormone-Dependent; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; PTEN Phosphohydrolase; Quinazolines | 2006 |
[Effectiveness of taxanes-based chemotherapy against hormone-refractory prostate carcinoma].
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Docetaxel; Gefitinib; Humans; Male; Mice; Middle Aged; Prognosis; Prostatic Neoplasms; Quality of Life; Quinazolines; Taxoids | 2006 |
[Molecular-targeted therapy for hormone-refractory prostate cancer].
Topics: Angiotensin Receptor Antagonists; Antineoplastic Agents; Atrasentan; Benzamides; Boronic Acids; Bortezomib; Calcitriol; Celecoxib; Cyclooxygenase 2 Inhibitors; Endothelin A Receptor Antagonists; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Male; Piperazines; Prostatic Neoplasms; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sulfonamides; Thalidomide; Vitamin D | 2006 |
Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cell Proliferation; Cells, Cultured; Ceramides; Cytochromes c; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Etoposide; Flow Cytometry; Gefitinib; Humans; Immunoenzyme Techniques; Male; Membrane Potential, Mitochondrial; Neoplasms, Hormone-Dependent; Prostate; Prostatic Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen | 2007 |
Derivatives of Iressa, a specific epidermal growth factor receptor inhibitor, are powerful apoptosis inducers in PC3 prostatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; ErbB Receptors; Gefitinib; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2007 |
Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Cytochromes c; Docetaxel; ErbB Receptors; Gefitinib; Hedgehog Proteins; Humans; Immunohistochemistry; Male; Membrane Potential, Mitochondrial; Neoplasm Invasiveness; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Quinazolines; Signal Transduction; Taxoids; Tumor Cells, Cultured; Veratrum Alkaloids | 2007 |
Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Gefitinib; Humans; Male; Nerve Growth Factor; Phosphorylation; Prostatic Neoplasms; Quinazolines; Receptor, ErbB-2; Receptor, Nerve Growth Factor; Receptor, trkA; Receptor, trkB; Signal Transduction; Time Factors | 2007 |
EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt.
Topics: Adenocarcinoma; Androgens; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cell Differentiation; Cell Line, Tumor; Culture Media, Serum-Free; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2007 |
Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Immunoprecipitation; Insulin Receptor Substrate Proteins; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Quinazolines; Receptor Cross-Talk; Receptors, Somatomedin; Signal Transduction | 2008 |
Gefitinib and bicalutamide show synergistic effects in primary cultures of prostate cancer derived from androgen-dependent naive patients.
Topics: Androgens; Anilides; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Gefitinib; Humans; Male; Nitriles; Prostatic Neoplasms; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Tosyl Compounds | 2007 |
Livedo reticularis with retiform purpura associated with gefitinib (Iressa).
Topics: Aged; Antineoplastic Agents; Drug Eruptions; Gefitinib; Humans; Livedo Reticularis; Male; Prostatic Neoplasms; Purpura; Quinazolines; Skin | 2007 |
Improvement of cytotoxic effects induced by mitoxantrone on hormone-refractory metastatic prostate cancer cells by co-targeting epidermal growth factor receptor and hedgehog signaling cascades.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Synergism; ErbB Receptors; Gefitinib; Hedgehog Proteins; Humans; Hydrogen Peroxide; Male; Membrane Potential, Mitochondrial; Mitoxantrone; Neoplasm Invasiveness; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Quinazolines; Signal Transduction; Veratrum Alkaloids | 2007 |
Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.
Topics: Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Chromones; ErbB Receptors; Gefitinib; Humans; Lapatinib; Male; Mitogen-Activated Protein Kinases; Morpholines; Neoplasms, Hormone-Dependent; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines | 2008 |
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
Topics: Aminopterin; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carboplatin; Cell Division; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Prostatic Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Time Factors; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Vulvar Neoplasms | 2000 |